SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 202 filers reported holding SAGE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $4,437,135 | -38.8% | 408,576 | +5.5% | 0.00% | -50.0% |
Q1 2024 | $7,254,985 | -19.1% | 387,139 | -6.5% | 0.00% | 0.0% |
Q4 2023 | $8,969,321 | +6.6% | 413,905 | +1.2% | 0.00% | 0.0% |
Q3 2023 | $8,416,952 | -54.2% | 408,987 | +4.6% | 0.00% | -60.0% |
Q2 2023 | $18,392,719 | +13.7% | 391,168 | +1.5% | 0.01% | 0.0% |
Q1 2023 | $16,172,097 | +10.0% | 385,417 | -0.0% | 0.01% | 0.0% |
Q4 2022 | $14,705,869 | -0.5% | 385,576 | +2.2% | 0.01% | 0.0% |
Q3 2022 | $14,780,000 | +23.8% | 377,415 | +2.1% | 0.01% | +25.0% |
Q2 2022 | $11,940,000 | +34.6% | 369,650 | +38.0% | 0.00% | +33.3% |
Q1 2022 | $8,869,000 | -19.5% | 267,945 | +3.4% | 0.00% | 0.0% |
Q4 2021 | $11,020,000 | -2.8% | 259,034 | +1.2% | 0.00% | -25.0% |
Q3 2021 | $11,341,000 | -27.0% | 255,933 | -6.4% | 0.00% | -20.0% |
Q2 2021 | $15,530,000 | -22.0% | 273,355 | +2.7% | 0.01% | -28.6% |
Q1 2021 | $19,916,000 | -11.2% | 266,072 | +2.6% | 0.01% | -22.2% |
Q4 2020 | $22,437,000 | +43.5% | 259,349 | +1.4% | 0.01% | +28.6% |
Q3 2020 | $15,640,000 | +48.7% | 255,889 | +1.2% | 0.01% | +40.0% |
Q2 2020 | $10,517,000 | +48.9% | 252,916 | +2.8% | 0.01% | +25.0% |
Q1 2020 | $7,064,000 | -59.5% | 245,934 | +1.9% | 0.00% | -55.6% |
Q4 2019 | $17,422,000 | -47.7% | 241,330 | +1.7% | 0.01% | -55.0% |
Q3 2019 | $33,292,000 | -19.2% | 237,304 | +5.5% | 0.02% | -20.0% |
Q2 2019 | $41,199,000 | +21.7% | 225,019 | +5.7% | 0.02% | +13.6% |
Q1 2019 | $33,860,000 | +89.4% | 212,885 | +14.1% | 0.02% | +57.1% |
Q4 2018 | $17,876,000 | -28.7% | 186,607 | +5.1% | 0.01% | -17.6% |
Q3 2018 | $25,080,000 | -6.6% | 177,551 | +3.5% | 0.02% | -15.0% |
Q2 2018 | $26,847,000 | -28.8% | 171,509 | -26.7% | 0.02% | -31.0% |
Q1 2018 | $37,682,000 | +20.9% | 233,945 | +23.6% | 0.03% | +16.0% |
Q4 2017 | $31,169,000 | +231.3% | 189,230 | +25.3% | 0.02% | +212.5% |
Q3 2017 | $9,409,000 | -14.5% | 151,026 | +9.3% | 0.01% | -20.0% |
Q2 2017 | $11,005,000 | +17.8% | 138,179 | +5.1% | 0.01% | +11.1% |
Q1 2017 | $9,342,000 | +40.9% | 131,440 | +1.2% | 0.01% | +28.6% |
Q4 2016 | $6,630,000 | +35.3% | 129,847 | +22.1% | 0.01% | +16.7% |
Q3 2016 | $4,900,000 | +128.9% | 106,387 | +49.8% | 0.01% | +100.0% |
Q2 2016 | $2,141,000 | +22.8% | 71,041 | +30.6% | 0.00% | +50.0% |
Q1 2016 | $1,744,000 | -25.1% | 54,379 | +36.2% | 0.00% | -33.3% |
Q4 2015 | $2,328,000 | +50.8% | 39,930 | +9.5% | 0.00% | +50.0% |
Q3 2015 | $1,544,000 | +6.3% | 36,477 | +83.3% | 0.00% | 0.0% |
Q2 2015 | $1,453,000 | +261.4% | 19,895 | +148.7% | 0.00% | +100.0% |
Q1 2015 | $402,000 | +37.2% | 8,000 | 0.0% | 0.00% | – |
Q4 2014 | $293,000 | – | 8,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
RA Capital Management | 350,933 | $49,569,000 | 2.65% |
Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |